TY - JOUR
T1 - The effect of minocycline on symptoms in schizophrenia
T2 - Results from a randomized controlled trial
AU - Weiser, Mark
AU - Levi, Linda
AU - Burshtein, Shimon
AU - Chiriță, Roxana
AU - Cirjaliu, Diana
AU - Gonen, Ilan
AU - Yolken, Robert
AU - Davidson, Michael
AU - Zamora, Daisy
AU - Davis, John M.
N1 - Publisher Copyright:
© 2018 Elsevier B.V.
PY - 2019/4
Y1 - 2019/4
N2 - Background: Studies have hypothesized that immunological abnormalities might contribute to schizophrenia, and basic science studies, as well as several clinical trials suggest that minocycline could be efficacious in ameliorating both positive and negative symptoms of schizophrenia. In this study we examined the effect of minocycline on schizophrenia in a large randomized controlled trial. Methods: We performed a 16-week, multi-center, double-blind, randomized, placebo-controlled study on 200 subjects with schizophrenia or schizoaffective disorder randomized to receive either minocycline (200 mg/day, n = 100), or placebo (n = 100) as an add-on to anti-psychotic treatment. The primary outcome measure was the PANSS total score. Results: Mixed models for repeated measures showed no significant difference between minocycline and placebo for total PANSS (p = 0.862), PANSS subscales, CGI or BACS. Conclusions: Minocycline did not improve symptoms or cognition in schizophrenia.
AB - Background: Studies have hypothesized that immunological abnormalities might contribute to schizophrenia, and basic science studies, as well as several clinical trials suggest that minocycline could be efficacious in ameliorating both positive and negative symptoms of schizophrenia. In this study we examined the effect of minocycline on schizophrenia in a large randomized controlled trial. Methods: We performed a 16-week, multi-center, double-blind, randomized, placebo-controlled study on 200 subjects with schizophrenia or schizoaffective disorder randomized to receive either minocycline (200 mg/day, n = 100), or placebo (n = 100) as an add-on to anti-psychotic treatment. The primary outcome measure was the PANSS total score. Results: Mixed models for repeated measures showed no significant difference between minocycline and placebo for total PANSS (p = 0.862), PANSS subscales, CGI or BACS. Conclusions: Minocycline did not improve symptoms or cognition in schizophrenia.
UR - http://www.scopus.com/inward/record.url?scp=85056704609&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2018.10.023
DO - 10.1016/j.schres.2018.10.023
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 30455075
AN - SCOPUS:85056704609
SN - 0920-9964
VL - 206
SP - 325
EP - 332
JO - Schizophrenia Research
JF - Schizophrenia Research
ER -